Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 629-640

  Fernández Guinea, Oscar ^a   Álvarez Cofiño, Almudena ^a   Eiró, Noemí ^a   González, Luis O ^a   Del Casar, José M ^a   Fernandez Garcia, Belen ^a   Lamelas, Maria L ^a   Andicoechea, Alejandro ^a   Vizoso, Francisco J ^a  

^a HOSPITAL DE JOVE   (Spain)

Author keywords

Invasive breast cancer; Microvascular density; MMP; TIMP; Tumor heterogeneity; Tumor stroma

Indexed keywords

COLLAGENASE 3; CYCLOPHOSPHAMIDE; FLUOROURACIL; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; METHOTREXATE; STROMELYSIN 3; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS; EARLY DIAGNOSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; WIDE EXCISION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 11; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; MICROVESSELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84882625337     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0428-2     Document Type: Article

References (59)

1. Lindmark G, Gerdin B, Sundberg C et al (1996) Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol 14:461-466
2. Ribatti D, Ponzoni M (2005) Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev 31:27-34
3. Shimizu T, Hino K, Tauchi K et al (2000) Predication of axillary lymph node metastasis by intravenous digital subtraction angiography in breast cancer, its correlation with microvascular density. Breast Cancer Res Treat 61:261-269
4. Zhao ZS, Zhou JL, Yao GY et al (2005) Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol 11:3227-3233
5. Fernandez-Aguilar S, Jondet M, Simonart T et al (2006) Microvessel and lymphatic density in tubular carcinoma of the breast: comparative study with invasive low-grade ductal carcinoma. Breast 15:782-785
6. Weidner N, Folkman J, Pozza F et al (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887
7. Bossi P, Viale G, Lee AK et al (1995) Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55:5049-5053
8. Busam KJ, Berwick M, Blessing K et al (1995) Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol 147:1049-1056
9. Hillen F, van de Winkel A, Creytens D et al (2006) Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Res 16:453-457
10. Marrogi AJ, Travis WD, Welsh JA et al (2000) Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6:4739-4744
11. Bhattacharya A, Toth K, Mazurchuk R et al (2004) Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 10:8005-8017
12. Garrido-Laguna I, Uson M, Rajeshkumar NV et al (2011) Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17:5793-5800
13. Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243-529
14. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732
15. Axelson H, Fredlund E, Ovenberger M et al (2005) Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16:554-563
16. Generali D, Berruti A, Brizzi MP et al (2006) Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12:4562-4568
17. McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13:534-540
18. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657-672
19. Demers M, Couillard J, Belanger S et al (2005) New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol 25:493-523
20. Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6:4823-4830
21. Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267-285
22. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG et al (1999) Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568-29571
23. Patterson BC, Sang QA (1997) Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272:28823-28825
24. Troyanovsky B, Levchenko T, Mansson G et al (2001) Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152:1247-1254
25. Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3:422-433
26. Gonzalez LO, Pidal I, Junquera S et al (2007) Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 97:957-963
27. Vizoso FJ, Gonzalez LO, Corte MD et al (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96:903-911
28. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
29. Gonzalez L, Corte MD, Vazquez J et al (2008) Study of matrix metalloproteinases and their tissular inhibitors in ductal "in situ" carcinomas of the breast. Histophatology 53:403-415
30. Parker RL, Huntsman DG, Lesack DW et al (2002) Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117:723-728
31. Gonzalez LO, Corte MD, Junquera S et al. (2009) Expression and prognostic significance of metalloproteases and their inhibitors in both luminal and basal-like phenotypes of breast carcinomas. Human Pathol 40:1224-1233
32. Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
33. Uzzan B, Nicolas P, Cucherat M et al (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64:2941-2955
34. Vermeulen PB, Gasparini G, Fox SB et al (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38:1564-1579
35. Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101:937-949
36. Ribatti D, Vacca A, Dammacco F (2003) New non-angiogenesis dependent pathways for tumour growth. Eur J Cancer 39:1835-1841
37. Yue WY, Chen ZP (2005) Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 53:997-1002
38. Traweek ST, Kandalaft PL, Mehta P et al (1991) The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 96:25-31
39. van de Rijn M, Hendrickson MR, Rouse RV (1994) CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol 25:766-771
40. Fernandez-Guinea O, Andicoechea A, Gonzalez LO et al (2010) Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer. BMC Cancer 10:8
41. Eberhard A, Kahlert S, Goede V et al (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388-1393
42. Graeber TG, Osmanian C, Jacks T et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91
43. Gordan JD, Simon MC (2007) Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17:71-77
44. Mabjeesh NJ, Amir S (2007) Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22:559-572
45. Semenza GL (2000) Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 106:809-812
46. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8:S62-S67
47. Choi JY, Jang YS, Min SY et al (2011) Overexpression of MMP-9 and HIF-1alpha in Breast Cancer Cells under Hypoxic Conditions. J Breast Cancer 14:88-95
48. Del Casar JM, Gonzalez LO, Alvarez E et al (2009) Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 116:39-52
49. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516
50. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174
51. Turk V, Kos J, Turk B (2004) Cysteine cathepsins (proteases)-on the main stage of cancer? Cancer Cell 5:409-410
52. Rifkin DB, Mazzieri R, Munger JS et al (1999) Proteolytic control of growth factor availability. Apmis 107:80-85
53. Manes S, Llorente M, Lacalle RA et al (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935-6945
54. Noe V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111-118
55. Fingleton B, Vargo-Gogola T, Crawford HC et al (2001) Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3:459-468
56. Baker AH, George SJ, Zaltsman AB et al (1999) Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79:1347-1355
57. Guedez L, McMarlin AJ, Kingma DW et al (2001) Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 158:1207-1215
58. Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245-2252
59. Wurtz SO, Schrohl AS, Sorensen NM et al (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12:215-227